Home › Viral Infections › NCT02532452
Third Party Viral Specific T-cells (VSTs)
RecruitingPhase 2
Third Party Viral Specific T-cells (VSTs) for Treatment of Viral Infections in Immunocompromised Patients
Who can join
2 Days · All sexes
Full eligibility criteria
Inclusion Criteria: * Immunocompromised patient with evidence of viral infection or reactivation * Age \>1 day * Recipients who have had a stem cell transplant must be at least 21 days after stem cell infusion * Clinical status must allow tapering of steroids to \< 0.5mg/kg prednisone or other steroid equivalent * Must be able to receive CTL infusion in Cincinnati * Informed consent obtained by PI or sub-investigator either in person or by phone Exclusion Criteria: * Active acute GVHD grades II-IV * Uncontrolled bacterial or fungal infection * Uncontrolled relapse of malignancy requiring treatment with chemotherapy * Infusion of ATG or alemtuzumab within 2 weeks of VST infusion * Biopsy confirmed acute rejection of solid organ transplant OR empiric treatment of suspected but not confirmed acute rejection of solid organ transplant within the last 30 days
About the study
The purpose of this study is to demonstrate that viral specific T-cells (a type of white blood cell) can be generated from an unrelated donor and given safely to patients with viral infections.
What is being tested
- Viral Specific VST Infusion (biological)
Sponsor: Children's Hospital Medical Center, Cincinnati · Participants: 1,000 · Started: Sep 2, 2015
Contact the study team
- Jamie Wilhelm · Phone: (513) 803-1102
Official record on ClinicalTrials.gov — NCT02532452
Locations in the U.S.
| Ohio | Akron Children's Hospital, Akron Cincinnati Children's Hospital Medical Center, Cincinnati The Ohio State University Wexner Medical Center - James Cancer Hospital, Columbus |
Conditions
From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.